Boundless Bio drops clinical-stage cancer drug over phase 1 data, shakes up C-suite

Boundless Bio’s freshman year on the public markets hasn’t been easy, with “modest” layoffs in the summer followed by news this week that the company is dropping a clinical-stage candidate and shaking up its C-suite.